Hummingbird Bioscience Licenses Novel Antibodies to Immunome

SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (Korea Bizwire) – Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed [...]